Phase I/IIa trial of the novel microtubule inhibitor BAL101553 in advanced solid tumors: Phase I completed

2562 Background: BAL101553 is a prodrug of the small molecule BAL27862, a novel microtubule-targeting agent (MTA) with potent activity in tumor models refractory to conventional MTAs. Its anti-canc...